Format

Send to

Choose Destination
Front Biosci (Elite Ed). 2016 Jan 1;8:46-60.

ALK inhibitors for clinical use in cancer therapy.

Author information

1
Department of Health Sciences, University of Milano-Bicocca, Milano, Italy.
2
Department of Health Sciences, University of Milano-Bicocca, Via Cadore 48, 20052 Monza, Italy, carlo.gambacorti@unimib.it.

Abstract

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase protein implicated in a variety of tumors, both solid and hematological. Few years ago crizotinib, an inhibitor of the receptor tyrosine kinases c-Met and ALK, demonstrated its activity in ALK positive non-small-cell lung cancer and other tumors with excellent toxicity profile. Subsequently several ALK inhibitors have been developed, offering new personalized treatment options. This review addresses some clinical considerations on the use of ALK inhibitors in ALK positive tumors and on the development of resistance to them.

PMID:
26709645
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Frontiers in Bioscience
Loading ...
Support Center